GlassScriptPhysician profile
David James Krause
NPI 1962450684
$8,365.55
in general payments reported to CMS, 2019-2025
35 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $942 · 2021: $1,166 · 2022: $1,053 · 2023: $1,375 · 2024: $1,803 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,811.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,773.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $945.36 | 2019-2025 | Jardiance |
| Amgen INC. | $898.05 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $765.77 | 2020-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $615.45 | 2019-2024 | Xarelto |
| Philips North America LLC | $480.84 | 2020-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (Ck6) Holter |
| Scpharmaceuticals INC. | $443.44 | 2024-2025 | |
| Pfizer INC. | $338.51 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $321.09 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $290.25 | 2023-2025 | Bodyguardian, Watchman Flx, Cds - Mct/Cem Monitoring |
| Merck Sharp & Dohme LLC | $233.59 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $172.89 | 2019-2024 | |
| Esperion Therapeutics, INC. | $152.27 | 2020-2025 | Nexletol |
| Bardy Diagnostics, INC. | $140.32 | 2019-2022 | |
| Amarin Pharma, INC. | $81.86 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $77.72 | 2022-2025 | Onpattro, Amvuttra |
| Bridgebio Pharma, INC. | $66.12 | 2025 | Attruby |
| Novo Nordisk INC | $65.54 | 2023-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $56.79 | 2019-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $53.58 | 2019-2025 | Uptravi, Opsumit |
| Irhythm Technologies, INC. | $50.46 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $45.05 | 2025 | |
| Lilly USA, LLC | $38.20 | 2025 | Zepbound, Mounjaro |
| Braemar Manufacturing, LLC | $35.97 | 2019 | |
| Glaxosmithkline, LLC. | $35.48 | 2025 | Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $28.53 | 2024 | Arcalyst |
| Abbott Laboratories | $24.77 | 2022 | |
| Mannkind Corporation | $24.25 | 2025 | |
| Baxter Healthcare | $22.74 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $19.54 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $15.53 | 2019 | |
| Astellas Pharma US INC | $14.89 | 2021 | |
| Preventice Services, LLC | $14.54 | 2021 | |
| Lundbeck LLC | $11.76 | 2020 | |
| Aegerion Pharmaceuticals, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Krause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.